EXELExelixisNot started yet
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Squamous Non-Small Cell Lung Cancer (NSCLC)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 26, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 60 (planned)
- Started
- Dec 15, 2026
- Main results expected
- Jun 15, 2028
- Fully finished
- Jun 15, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) at 6 Months (PFS-6) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as Assessed by Investigator
Measured over: 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07845786 · record last updated 2026-09-29 · checked 2026-11-09 15:47 UTC